AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying therapies and innovative detection tools for amyloid-related…
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through nose-to-brain neurocircuitry, today announced the appointment of Nick Tressler as…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new class of targeted macrocycle therapeutics designed to address some of…
Celltrion Receives Health Canada Approval for Eydenzelt®, a Biosimilar Referencing Eylea® Celltrion, Inc. has announced a major regulatory milestone with the approval of Eydenzelt® by Health Canada. The newly approved biosimilar references Eylea® (aflibercept 2mg) and will be available to…
Otsuka Announces FDA Accelerated Approval of VOYXACT® for Proteinuria Reduction in Adults with Primary IgA Nephropathy Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated…
Enigma Biomedical USA Awarded $2 Million Grant from The Michael J. Fox Foundation to Advance Novel α-Synuclein PET Imaging Biomarker for Parkinson’s Disease Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing manufacturing presence in Maryland, further solidifying the state’s role as…
BeOne Medicines Demonstrates Scientific Leadership in B-Cell Cancers at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a rapidly expanding global oncology innovator, is set to showcase one of the most comprehensive and data-rich hematology portfolios at…
Oncolytics Biotech® Aligns with FDA on Pivotal Phase 3 Study Design for Pelareorep in First-Line Metastatic Pancreatic Cancer Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company advancing pelareorep, announced that it has reached alignment with…
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing leadership in immuno-oncology, announced the appointment of José Iglesias, M.D.,…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a novel gene editing platform designed to counteract drug resistance in…
